Artificial Intelligence Can Predict Personalized Immunotherapy Outcomes in Cancer.

Journal: Cancer immunology research
Published Date:

Abstract

The rapid advancement of artificial intelligence (AI) technologies has opened new avenues for advancing personalized immunotherapy in cancer treatment. This review highlights current research progress in applying AI to optimize the use of immunotherapy for patients with cancer. Recent studies demonstrate that AI models can accurately diagnose cancers and discover biomarkers by integrating multi-omics and imaging data, establish predictive models to estimate treatment responses and adverse reactions, formulate personalized treatment plans integrating multiple modalities by considering various factors, and achieve precise patient stratification and clinical trial matching, thereby addressing specific obstacles throughout processes from diagnosis to treatment in personalized immunotherapy. Furthermore, this review also discusses the challenges and limitations faced by AI in clinical applications, such as difficulties in data acquisition, low quality of data, poor interpretability of models, and insufficient generalization ability. Finally, we outline future research directions, including optimizing data management, developing explainable AI, and improving the generalization ability of models. These efforts aim to optimize the role of AI in personalized immunotherapy and promote the development of precision medicine. To ensure the clinical applicability of these AI models, large-scale studies, multi-omics integration, and prospective clinical trials are necessary.

Authors

  • Ling Huang
    School of Civil Engineering and Transportation, South China University of Technology, Guangzhou, 510640, China.
  • Xuewei Wu
    Department of Radiology, the First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
  • Jingjing You
    Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Zhe Jin
    Zhejiang University, College of Computer Science and Technology, Hangzhou, China.
  • WenLe He
    Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China.
  • Jie Sun
    College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, 150081, People's Republic of China.
  • Hui Shen
    College of Mechatronics and Automation, National University of Defense Technology, Changsha, China.
  • Xin Liu
    Peking University Institute of Advanced Agricultural Sciences, Shandong Laboratory of Advanced Agricultural Sciences, Weifang, Shandong, China.
  • Xin Yue
    State Key Laboratory of Bioactive Molecules and Druggability Assessment, The First Affiliated Hospital of Jinan University, Guangzhou, China.
  • Wenli Cai
    Radiology Imaging Laboratory, Harvard Medical School, Boston, Massachusetts 02114, USA.
  • Shuixing Zhang
    Medical Imaging Center, First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, PR China; Institute of Molecular and Functional Imaging, Jinan University, Guangzhou, Guangdong, PR China. Electronic address: shui7515@126.com.
  • Bin Zhang
    Department of Psychiatry, Sleep Medicine Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.